New Delhi, November 11
Two days after US pharma giant Pfizer claimed 90 per cent effectiveness for its Covid vaccine, Russia today announced that the world’s first registered vaccine against SARS-CoV2, Sputnik V, had demonstrated 92 per cent efficacy after the second dose.
The Russian Direct Investment Fund said the efficacy results were based on the first interim data from the largest double-blind, randomised, placebo-controlled phase-III clinical trials in Russia involving 40,000 volunteers.
Currently, Sputnik V phase III clinical trials are approved and are undergoing in India, Belarus, the UAE and Venezuela. “The research data will be provided to the national regulators of countries interested in purchasing the vaccine in order to streamline the registration process,” it said. — TNS